AI-enhanced whole-body CT to read bone marrow genetics and treatment response in multiple myeloma
AI-assisted quantitative photon-counting-detector CT imaging for cytogenetic risk prediction and treatment response in multiple myeloma
['FUNDING_R01'] · MAYO CLINIC ROCHESTER · NIH-11305974
This project uses a new whole-body photon-counting CT with AI to identify genetic risk features and track treatment response in people with multiple myeloma.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | MAYO CLINIC ROCHESTER (nih funded) |
| Locations | 1 site (ROCHESTER, UNITED STATES) |
| Trial ID | NIH-11305974 on ClinicalTrials.gov |
What this research studies
If I have multiple myeloma, the team would use a new type of CT scanner that counts individual X-rays along with AI to examine bone marrow across my whole skeleton. They plan to train deep-learning models to link CT image features to cytogenetic (genetic) risk markers from tumor cells. The project also aims to measure changes in marrow and lesion fat fraction on the CT scans as a sign of treatment response. The work involves developing and validating these AI models using clinical scans and known genetic test results so the imaging could complement or reduce the need for single-site bone marrow biopsies.
Who could benefit from this research
Good fit: People with a diagnosis of multiple myeloma who need genetic risk information or monitoring during treatment would be ideal candidates for this work.
Not a fit: People without multiple myeloma, those who cannot undergo CT scans (for example, pregnancy or certain medical contraindications), or those without access to photon-counting CT may not benefit from this approach.
Why it matters
Potential benefit: If successful, this could offer a noninvasive way to detect high-risk genetic features and monitor treatment response throughout the skeleton.
How similar studies have performed: AI and radiomics approaches have shown promise for predicting genomics and treatment response in other cancers and with PET/MRI in myeloma, but using photon-counting CT for cytogenetic risk is a novel application.
Where this research is happening
ROCHESTER, UNITED STATES
- MAYO CLINIC ROCHESTER — ROCHESTER, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: BAFFOUR, FRANCIS — MAYO CLINIC ROCHESTER
- Study coordinator: BAFFOUR, FRANCIS
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.